BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27467588)

  • 1. Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells.
    Winter U; Mena HA; Negrotto S; Arana E; Pascual-Pasto G; Laurent V; Suñol M; Chantada GL; Carcaboso AM; Schaiquevich P
    PLoS One; 2016; 11(7):e0160094. PubMed ID: 27467588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis.
    Yuan F; Shi H; Ji J; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
    Oncol Rep; 2015 Apr; 33(4):1753-62. PubMed ID: 25634241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Safety, and Efficacy of Intravitreal Digoxin in Preclinical Models for Retinoblastoma.
    Winter U; Buitrago E; Mena HA; Del Sole MJ; Laurent V; Negrotto S; Francis J; Arana E; Sgroi M; Croxatto JO; Djaballah H; Chantada GL; Abramson D; Schaiquevich P
    Invest Ophthalmol Vis Sci; 2015 Jul; 56(8):4382-93. PubMed ID: 26176875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
    Merritt WM; Nick AM; Carroll AR; Lu C; Matsuo K; Dumble M; Jennings N; Zhang S; Lin YG; Spannuth WA; Kamat AA; Stone RL; Shahzad MM; Coleman RL; Kumar R; Sood AK
    Mol Cancer Ther; 2010 Apr; 9(4):985-95. PubMed ID: 20371710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer.
    Aljuffali IA; Mock JN; Costyn LJ; Nguyen H; Nagy T; Cummings BS; Arnold RD
    Cancer Biol Ther; 2011 Sep; 12(5):407-20. PubMed ID: 21709443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
    Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
    Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma.
    Levitt JM; Jian W; Lerner SP; Sonpavde G
    Urol Oncol; 2013 Feb; 31(2):234-40. PubMed ID: 21723160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
    Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
    Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
    Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
    Di Desidero T; Xu P; Man S; Bocci G; Kerbel RS
    Oncotarget; 2015 Dec; 6(40):42396-410. PubMed ID: 26623560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model.
    Wu H; Xin Y; Zhao J; Sun D; Li W; Hu Y; Wang S
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):879-87. PubMed ID: 21290245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of retinoblastoma tumor cell death after focal chemotherapy, radiation, and vascular targeting therapy in a mouse model.
    Jockovich ME; Suarez F; Alegret A; Piña Y; Hayden B; Cebulla C; Feuer W; Murray TG
    Invest Ophthalmol Vis Sci; 2007 Dec; 48(12):5371-6. PubMed ID: 18055783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.
    Benelli R; Monteghirfo S; Balbi C; Barboro P; Ferrari N
    Int J Cancer; 2009 Jun; 124(12):2989-96. PubMed ID: 19319982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
    Merritt WM; Danes CG; Shahzad MM; Lin YG; Kamat AA; Han LY; Spannuth WA; Nick AM; Mangala LS; Stone RL; Kim HS; Gershenson DM; Jaffe RB; Coleman RL; Chandra J; Sood AK
    Cancer Biol Ther; 2009 Aug; 8(16):1596-603. PubMed ID: 19738426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
    Laurie NA; Gray JK; Zhang J; Leggas M; Relling M; Egorin M; Stewart C; Dyer MA
    Clin Cancer Res; 2005 Oct; 11(20):7569-78. PubMed ID: 16243833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
    Ng SS; Sparreboom A; Shaked Y; Lee C; Man S; Desai N; Soon-Shiong P; Figg WD; Kerbel RS
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4331-8. PubMed ID: 16857808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
    Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
    Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
    Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
    Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.
    Shi S; Tao L; Song H; Chen L; Huang G
    APMIS; 2014 May; 122(5):380-91. PubMed ID: 24628659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.